Publications by authors named "Heinrich Binsfeld"
Article Synopsis
- A study comparing once-daily OROS hydromorphone ER with twice-daily oxycodone CR showed that both medications effectively reduced chronic pain in patients, with OROS hydromorphone being noninferior.
- Over 28 weeks, participants reported similar improvements in pain levels, quality of life, and overall treatment convenience, with a slightly higher percentage finding OROS hydromorphone's dosing more convenient.
- Most patients expressed high satisfaction with both medications' tolerability and efficacy, with both treatments maintaining their effectiveness over a year, and very few patients discontinued due to side effects.
This was a randomized, open-label, comparative, parallel group study designed to demonstrate the noninferiority of once-daily OROS(®) hydromorphone compared with twice-daily sustained-release (SR) oxycodone in subjects with chronic noncancer pain severe enough to require continuous opioid therapy. The core phase (24 weeks) consisted of titration and maintenance periods. This was followed by an optional extension phase (28 weeks), which collected data used to assess long-term safety and efficacy outcomes.
View Article and Find Full Text PDF